312 related articles for article (PubMed ID: 34484468)
101. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
[TBL] [Abstract][Full Text] [Related]
102. Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern.
Goto E; Taki T; Nomura K; Miyakami Y; Miyoshi T; Tane K; Samejima J; Aokage K; Nagamine M; Sakashita S; Sakamoto N; Kojima M; Suzuki K; Tsuboi M; Ishii G
Lung Cancer; 2024 Jun; 192():107830. PubMed ID: 38805901
[TBL] [Abstract][Full Text] [Related]
103. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
[TBL] [Abstract][Full Text] [Related]
104. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.
Kirchner M; Kluck K; Brandt R; Volckmar AL; Penzel R; Kazdal D; Endris V; Neumann O; Seker-Cin H; Goldschmid H; Glade J; Allgäuer M; Kriegsmann M; Winter H; Muley T; Perner S; Frost N; Reck M; Fröhling S; Schirmacher P; Thomas M; Budczies J; Christopoulos P; Stenzinger A
ESMO Open; 2021 Oct; 6(5):100253. PubMed ID: 34487971
[TBL] [Abstract][Full Text] [Related]
105. Deep exploration of immune function in EGFR wild-type and mutated lung adenocarcinomas by gene expression profiling: role of TRAIL-R2 (TNFRSF10B) in patient treatment and outcome.
Chang WC; Yeh YC; Ho HL; Chou TY
Hum Pathol; 2022 Aug; 126():9-18. PubMed ID: 35550831
[TBL] [Abstract][Full Text] [Related]
106. Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma.
Xiao G; Li L; Tanzhu G; Liu Z; Gao X; Wan X; Xiao D; Chen L; Xia X; Zhou R
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868569
[TBL] [Abstract][Full Text] [Related]
107. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
108. Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma.
Szentkereszty M; Ladányi A; Gálffy G; Tóvári J; Losonczy G
Lung Cancer; 2024 Jun; 192():107824. PubMed ID: 38761665
[TBL] [Abstract][Full Text] [Related]
109. Multi-omics analysis of m
Wu X; Bai Z
Sci Rep; 2021 Oct; 11(1):20921. PubMed ID: 34686691
[TBL] [Abstract][Full Text] [Related]
110. Clinical, Genomic, and Transcriptomic Featurses of Lung Adenocarcinoma With Uncommon EGFR Mutation.
Hayasaka K; Takeda H; Sakurada A; Matsumura Y; Abe J; Shiono S; Notsuda H; Suzuki H; Endo M; Motohashi H; Okada Y
Clin Lung Cancer; 2024 Jan; 25(1):e43-e51. PubMed ID: 37985312
[TBL] [Abstract][Full Text] [Related]
111. Clinicopathological and molecular characterization of resected lung adenocarcinoma: Correlations with histopathological grading systems in Chinese patients.
Xia W; Zhang S; Ye Y; Xiao H; Zhang Y; Ning G; Zhang Y; Wang W; Fei GH
Pathol Res Pract; 2024 Jul; 259():155359. PubMed ID: 38810376
[TBL] [Abstract][Full Text] [Related]
112. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
Cheng W; Xu B; Zhang H; Fang S
Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
[TBL] [Abstract][Full Text] [Related]
113. EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.
Liu X; Li X; Zhang C; Jin J; Wang Z; Xiao R; Sun K; Wang J; Zhong W; Yang F
Lung Cancer; 2022 May; 167():78-86. PubMed ID: 35427848
[TBL] [Abstract][Full Text] [Related]
114. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.
Akhave N; Zhang J; Bayley E; Frank M; Chiou SH; Behrens C; Chen R; Hu X; Parra ER; Lee WC; Swisher S; Solis L; Weissferdt A; Moran C; Kalhor N; Zhang J; Scheet P; Vaporciyan AA; Sepesi B; Gibbons DL; Heymach JV; Lee JJ; Wistuba II; Andrew Futreal P; Zhang J; Fujimoto J; Reuben A
Lung Cancer; 2022 Oct; 172():19-28. PubMed ID: 35973335
[TBL] [Abstract][Full Text] [Related]
115. Genetic dissection of intratumor heterogeneity of PD-L1 expression in EGFR-mutated lung adenocarcinoma.
Kunimasa K; Hirotsu Y; Amemiya K; Honma K; Nakamura H; Nishino K; Omata M
Thorac Cancer; 2023 Aug; 14(22):2210-2215. PubMed ID: 37442887
[TBL] [Abstract][Full Text] [Related]
116. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas.
Arolt C; Meyer M; Ruesseler V; Nachtsheim L; Wuerdemann N; Dreyer T; Gattenlöhner S; Wittekindt C; Buettner R; Quaas A; Klussmann JP
Cancer Immunol Immunother; 2020 Jul; 69(7):1363-1373. PubMed ID: 32232506
[TBL] [Abstract][Full Text] [Related]
117. [Altered Treg and IL-1A Expression in the Immune Microenvironment
of Lung Squamous-cell Cancer after EGFR Blockade].
He H; Qi L; Hou Y
Zhongguo Fei Ai Za Zhi; 2017 Mar; 20(3):143-148. PubMed ID: 28302215
[TBL] [Abstract][Full Text] [Related]
118. The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
Lu Y; Sun Y; Zhang J; Kong M; Zhao Z; Sun B; Wang Y; Jiang Y; Chen S; Wang C; Tong Y; Wen L; Huang M; Wu F; Zhang L
Cancer Lett; 2024 Aug; 596():217020. PubMed ID: 38849009
[TBL] [Abstract][Full Text] [Related]
119. Genetic mutation profiles and immune microenvironment analysis of pulmonary enteric adenocarcinoma.
Xie M; Chen D; Li Y; Liu X; Kuang D; Li X
Diagn Pathol; 2022 Feb; 17(1):30. PubMed ID: 35172862
[TBL] [Abstract][Full Text] [Related]
120. The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis.
Zheng Y; Hao S; Xiang C; Han Y; Shang Y; Zhen Q; Zhao Y; Zhang M; Zhang Y
Front Oncol; 2021; 11():592854. PubMed ID: 34178613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
